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A Comparative Study of Three Different Types  
of Stem Cells for Treatment of Rat Spinal Cord Injury
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Nataliya Romanyuk,* Kristyna Karova,*‡ Kristyna Zaviskova,*‡ Jana Dubisova,*‡  
Sarka Kubinova,* Raj Murali,† Eva Sykova,*‡ Meena Jhanwar-Uniyal,† and Pavla Jendelova*‡
*Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic
† New York Medical College, Valhalla, NY, USA
‡Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic
Three different sources of human stem cells—bone marrow-derived mesenchymal stem cells (BM-MSCs), 
neural progenitors (NPs) derived from immortalized spinal fetal cell line (SPC-01), and induced pluripotent 
stem cells (iPSCs)—were compared in the treatment of a balloon-induced spinal cord compression lesion in 
rats. One week after lesioning, the rats received either BM-MSCs (intrathecally) or NPs (SPC-01 cells or iPSC-
NPs, both intraspinally), or saline. The rats were assessed for their locomotor skills (BBB, flat beam test, and 
rotarod). Morphometric analyses of spared white and gray matter, axonal sprouting, and glial scar formation, 
as well as qPCR and Luminex assay, were conducted to detect endogenous gene expression, while inflam-
matory cytokine levels were performed to evaluate the host tissue response to stem cell therapy. The highest 
locomotor recovery was observed in iPSC-NP-grafted animals, which also displayed the highest amount of 
preserved white and gray matter. Grafted iPSC-NPs and SPC-01 cells significantly increased the number of 
growth-associated protein 43 (GAP43+) axons, reduced astrogliosis, downregulated Casp3 expression, and 
increased IL-6 and IL-12 levels. hMSCs transiently decreased levels of inflammatory IL-2 and TNF-a. These 
findings correlate with the short survival of hMSCs, while NPs survived for 2 months and matured slowly 
into glia- and tissue-specific neuronal precursors. SPC-01 cells differentiated more in astroglial phenotypes 
with a dense structure of the implant, whereas iPSC-NPs displayed a more neuronal phenotype with a loose 
structure of the graft. We concluded that the BBB scores of iPSC-NP- and hMSC-injected rats were superior 
to the SPC-01-treated group. The iPSC-NP treatment of spinal cord injury (SCI) provided the highest recovery 
of locomotor function due to robust graft survival and its effect on tissue sparing, reduction of glial scarring, 
and increased axonal sprouting.
Key words: Spinal cord injury (SCI); iPSC-derived human neural progenitors; Inflammatory response; 
Human fetal neural stem cells; Human mesenchymal stem cells (hMSCs) 
INTRODUCTION
The spinal cord is prone to injuries that result in damage 
to the existing neural structures, leading to the destruc-
tion of locomotor and sensory pathways. This process 
is followed by secondary damage processes, including a 
local immune response, cavitation, glial scar formation, 
and tissue atrophy, which enlarge the primary insult lead-
ing to impaired regeneration1,2. In recent years, stem cell 
application after spinal cord injury (SCI) has generated 
promising results. A variety of stem cells have shown 
their potential for neurotransplantation. Transplanted stem 
cells can either repair damaged tissue by replacing cells 
destroyed during the primary insult or rescue cells in the 
injured spinal cord by producing cytokines (interleukins) 
and neurotrophic factors that facilitate regeneration or 
revascularization, thus reducing glial scar formation.
Mesenchymal stem cells (MSCs) possess self-renewal 
properties and are highly multipotent, giving rise to dif-
ferent cells of mesodermal origin such as adipocytes, 
chondrocytes, and osteocytes3,4. Although MSCs are often 
considered for stem cell therapy in SCI due to their anti-
inflammatory5, immunomodulatory6, and neuroprotective 
properties7,8, their ability to functionally replace neurons 
and glial cells remains highly debatable9. Furthermore, 
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MSCs can secrete a whole set of neurotrophic, growth, and 
angiogenic factors10–13, which exert a paracrine effect that 
can increase neuronal survival, stimulate axonal regen-
eration and endogenous angiogenesis, and thus enhance 
functional recovery. The possibility of autologous trans-
plantation using MSCs has drawn the interest of many 
scientific groups14–16. The majority of clinical studies 
using MSC transplantation to treat SCI are in phase 1 or 2, 
and their number is increasing, suggesting that despite 
several drawbacks that still need to be addressed at basic 
and preclinical levels, MSCs are considered potentially 
beneficial for translational studies. The cells used in clini-
cal trials are usually autologous to minimize the risk of 
rejection and are often administered intrathecally (IT) to 
avoid invasive surgical interventions.
Neural stem cells (NSCs) or neural progenitors (NPs) 
are multipotent cells with the ability to differentiate into 
neurons, oligodendrocytes, and astrocytes. NSCs are pres-
ent in the adult as well as developing central nervous sys-
tem (CNS) and can be isolated and expanded in vitro17–20 
or prepared as differentiated derivatives from embryonic21,22 
or induced pluripotent stem cells (iPSCs)23,24. The use 
of NPs in repairing the damaged spinal cord is gener-
ally focused on the replacement of loss as well as on 
trophic support of the remaining host nervous tissue25. 
Functional improvement assessed by the Basso, Beattie, 
and Bresnahan (BBB) locomotor scale has been reported 
by several authors after the transplantation of NSCs in 
SCI animals26–30. The source of implanted NSCs seems 
to play an important role in defining their impact and 
fate after SCI17,24,26,31. Since it is difficult to obtain fetal 
tissue in the required quantity and quality, immortalized 
cell lines have been developed using various techniques 
worldwide. One of these approaches is conditionally 
immortalized neuroepithelial stem cell lines, in which the 
immortalizing gene is downregulated upon transplanta-
tion into the host tissue. The technology (c-mycERTAM) 
employed to achieve conditional growth control is a 
fusion protein composed of a growth-promoting gene 
(c-myc) and a hormone receptor that is regulated by a 
synthetic drug, 4-hydroxy-tamoxifen (4-OHT)32. One of 
these cell lines, CTX0E03, has recently been approved 
in the UK for a clinical phase II trial in stroke patients 
(http://clinicaltrials.gov/show/NCT02117635).
iPSCs, originally described by Takahashi and 
Yamanaka33, are derived from differentiated cells by 
various reprogramming techniques by introducing spe-
cific transcription factors responsible for pluripotency. 
Currently, a variety of methods have been developed to 
derive iPSCs34,35. Human (h)NSCs derived from iPSCs 
have already shown strong potential in the experimental 
treatment of SCI24,28,31,36. Despite some unresolved issues 
raising concern (such as teratoma formation, the immuno-
genicity of iPSC-derived cells37, and epigenetic factors), 
the first clinical trial using iPSCs in the damaged retina 
has started in Japan38. Recently, the possibility of clinical 
application of allogenic precursor cells derived from iPSC 
lines is under investigation in nonhuman primates39,40.
In this investigation, we compared human bone marrow- 
derived mesenchymal stem cells (BM-MSCs) manufac-
tured under good manufacturing practices (GMPs) and 
two types of NPs, including cells from a human condi-
tional fetal spinal line (SPC-01, c-mycERTAM technol-
ogy), and human induced pluripotent stem cell-derived 
neural progenitors (iPSC-NPs) in the treatment of a 
clinically relevant SCI model of balloon-induced spinal 
cord compression in rats. The route of stem cell delivery 
was also chosen according to the most appropriate clini-
cal application of each stem cell type for SCI to provide 
robust preclinical data for cell therapy translation. We 
evaluated the effect of the application of the three cell 
types on locomotor recovery (BBB, flat beam test, and 
rotarod). Histological and immunohistochemical analy-
ses were performed to assess white and gray matter (WM/
GM) sparing, axonal sprouting, and astrogliosis, while 
the immunomodulatory effect of the implanted cells was 
evaluated by an analysis of cytokines released after SCI 
(Luminex assay). Quantitative polymerase chain reaction 
(qPCR) was used to compare and evaluate the expression 
of selected endogenous growth factors, caspase 3, and 
M1- and M2-related macrophage genes after cell treat-
ment in SCI.
MATERIALS AND METHODS
Cell Cultures
Human (h)MSCs were obtained based on the informed 
consent from patients enrolled in the clinical trial 
AMSC-DSD-001 and were provided by Bioinova Ltd. 
(Prague, Czech Republic). Cells were prepared under 
GMP conditions and supplied in 1.5 ml of cell suspen-
sion in Nunc (suspension of autologous MSC 3P). The 
mononuclear fraction containing hMSCs was separated 
from the bone marrow of healthy donors by gradient 
separation using 25% Gelofusine (B. Braun, Melsungen, 
Germany). The cells were expanded in minimal essen-
tial medium (MEM) Eagle alpha media (Lonza, Basel, 
Switzerland), supplemented with 5% mixed allogeneic 
thrombocyte lysate (Bioinova Ltd.) and 10 µg/ml gen-
tamicin (Lek Pharmaceuticals, Ljublanja, Slovenia). 
Cells (third passage) were analyzed using fluorescence-
activated cell sorting (FACS) (LSR II; BD Biosciences, 
San Diego, CA, USA) and used for transplantation. The 
cells were positive for CD73, CD105, CD90, and major 
histocompatibility complex (MHC) class I, and negative 
for CD45, CD14, CD34, CD16, CD3, CD19, CD80, and 
MHC class II surface molecules. Control differentiation 
protocol (adipogenic, osteogenic, and chondrogenic) was 
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performed to confirm the multipotent potential of the 
cells. Cell phenotyping was performed by Bioinova Ltd.
The human neural conditionally immortalized cell line 
(SPC-01) was prepared according to the protocol described 
in previous publications17,41. A retroviral vector encod-
ing the immortalizing construct (c-mycERTAM) was 
used to immortalize the cells from 10-week-old human 
fetal spinal cords. Additionally, the SPC-01 cells were 
transduced by green fluorescent protein (GFP). SPC-01 
GFP+ cells were cultured in laminin-coated tissue culture 
flasks in growth media, composed of Dulbecco’s modi-
fied Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, 
MO, USA)/F12 supplemented with human serum albu-
min (HAS; 0.03%; Baxter Healthcare Ltd., Norfolk, 
UK), human transferrin (100 µg/ml), L-glutamine (2 mM), 
putrescine dihydrochloride (16.2 µg/ml), sodium selenite 
(selenium; 40 ng/ml), human insulin (5 µg/ml), epidermal 
growth factor (EGF; 20 ng/ml), progesterone (60 ng/ml), 
and 4-OHT (100 nM) (all from Sigma-Aldrich), and 
fibroblast growth factor (FGF; 10 ng/ml; PeproTech, 
London, UK). The medium was changed three times per 
week. SPC-01 GFP+ cells from passages 26–29 were used 
in all experiments.
iPSC-NPs were prepared according to Polentes et al.42. 
In order to derive the human iPSC line, a lentivirus-
 mediated combination of octamer-binding transcription 
factor 4 (OCT4), sex-determining region Y-box 2 (SOX2), 
NANOG, and LIN28 human cDNA33 (prepared plasmid 
from Addgene, Cambridge, MA, USA) was used for 
transduction of female (IMR90) human fetal lung fibro-
blasts (ATCC; Manassas, VA, USA). Clone selection, 
validation of the iPSC line, and derivation of neuronal 
progenitors are described in detail42. Cells were routinely 
cultured in tissue culture flasks coated with laminin (10 µg/
ml in DMEM/F12) and poly-L-ornithine (0.002% in dis-
tilled water), both from Sigma-Aldrich. Growth medium 
comprising DMEM/F12 and Neurobasal medium (1:1), 
N2 supplement (1:100), B27 supplement (1:50; GIBCO, 
Life Technologies, Grand Island, NY, USA), L-glutamine 
(2 mM; Sigma-Aldrich), penicillin and streptomycin 
(50 U/ml; GIBCO), EGF (10 ng/ml), FGF (10 ng/ml), 
and brain-derived neurotrophic factor (BDNF; 20 ng/ml; 
PeproTech) was changed three times per week. A 7-day 
process of predifferentiation in the same medium, except 
for the omission of FGF and EGF, was used prior to 
transplantation of iPSC-NPs.
Animals
Ten-week-old male Wistar rats (Anlab, Prague, Czech 
Republic) (n = 225) with body weights of 300 ± 15 g were 
used. The rats were housed in pairs and maintained in 
environmentally controlled rooms (22°C–24°C) with a 12-h 
light/dark cycle. Seven days after injury, all rats were 
implanted either IT with MSCs (n = 47) or saline (n = 38), 
or intraspinally (IS) at the level of SCI with SPC-01 cells 
(n = 50), iPSC-NPs (n = 49), or saline (n = 41). Animals 
used for cytokine assay (sacrificed 10, 14, and 28 days 
after injury) and gene expression assay (sacrificed 10 and 
28 days after injury) were not used for behavioral evalu-
ation. At each time point, five rats per group were allo-
cated for protein expression studies (Luminex, Austin, 
TX, USA) and for qPCR. The second group of rats 
(saline, n = 16; MSCs, n = 22; SPC-01, n = 25; iPSC-NPs, 
n = 24) was used for behavioral, histological, immunohis-
tochemical, and 2-month qPCR studies. Histological and 
immunohistochemical evaluation was performed either 
on longitudinal spinal sections [saline (IS + IT), n = 7 + 6; 
MSCs, n = 11; SPC-01, n = 14; iPSC-NPs, n = 11] or on 
cross-sections [saline (IS + IT), n = 8 + 7; MSCs, n = 7; 
SPC-01, n = 8; iPSC-NPs, n = 10] 2 months after grafting. 
Preliminary experiments were performed to determine 
the cell survival of the transplanted cells (MSCs, n = 4; 
SPC-01, n = 3; iPSC-NPs, n = 3) 2 weeks following their 
administration. All experiments were performed in accor-
dance with the European Communities Council Directive 
on September 22, 2010 (2010/63/EU) regarding the use 
of animals in research and were approved by the ethics 
committee of the Institute of Experimental Medicine, 
Academy of Sciences of the Czech Republic.
SCI and Cell Transplantation
A balloon-induced spinal cord compression lesion was 
used as the model of SCI in rats43. The surgical procedures 
were performed under sterile conditions. After the induc-
tion of anesthesia (3.5 vol%; Forane; AbbVie, Prague, 
Czech Republic) and an intramuscular injection of anal-
gesic (Rimadyl 50 µl; Zoetis, Prague, Czech Republic), 
1 cm of 2-French Fogarty catheter was inserted into the 
epidural space through a laminectomy at T10. Body tem-
perature was maintained at 37°C during the entire surgi-
cal procedure. Spinal cord compression was induced by 
inflation of the balloon with 15 µl of saline for 5 min at 
the T8 spinal level and then the catheter was emptied, 
removed, and the wound was sutured in anatomical layers. 
Gentamicin (5 mg/kg; Sandoz, Prague, Czech Republic) 
was given intramuscularly within 10 days to prevent 
postsurgical infection. Retention of urine was prevented 
by manual bladder expression performed twice per day. 
Seven days after SCI, hMSCs (5 ´  105/50 µl saline) were 
injected into the subdural space through the L5–L6 inter-
vertebral space according to De la Calle and Paino44. NPs, 
SPC-01 cells (5 ´  105/5 µl saline), or iPSC-NPs (5 ´  105/ 
5 µl saline) were implanted in situ into the lesioned tissue 
at the area of Th8–9 according to Amemori et al.26. Control 
rats for the MSC group were injected with 50 µl of saline 
into the L5–L6 intervertebral space. Control animals for 
the SPC and iPSC-NP groups were injected with 5 µl 
of saline into the lesioned tissue. A daily injection of 
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immunosupressants [cyclosporine A (Sandimmune; 10 mg/ 
kg; Novartis, Prague, Czech Republic) and azathioprine 
sodium (Imuran; 2 mg/kg; GlaxoSmithKline, Prague, 
Czech Republic)] was used to prevent the rejection of the 
cell transplants and was performed in all groups of ani-
mals (including controls).
Behavioral Assessment
BBB Test. Basic locomotor functions were evaluated 
using the BBB open field test45. Two independent exam-
iners scored the locomotor performance of experimental 
rats placed into a circular arena on a scale of 0–21 for 
approximately 4 min once a week, starting from the first 
week after SCI.
Flat Beam Test. The flat beam test was used to assess 
motor function and forelimb–hindlimb coordination. The 
central part of the beam (1 m long) was used to evalu-
ate the walking distance and velocity. The latency and 
the trajectory were recorded for a period of 60 s using a 
video-tracking system (TSE-Systems Inc., Bad Homburg, 
Germany). After pretraining, testing was performed twice 
per day for 3 consecutive days. The rats were examined 
before surgery and then every week from the second week 
after lesion induction. The rats were scored on a 5-point 
scale modified from Goldstein46, reflecting their ability to 
cross the beam.
Rotarod Test. Motor function and the coordination of 
the hindlimbs were examined in a four-lane rotarod unit 
(Ugo Basile, Comerio, Italy). Rats underwent 5 consecu-
tive days of training prior to the injury. In training mode, 
the rod was accelerated from 5 to 10 rpm over a period of 
5 min. Lesioned rats were allowed to stay on the rod at a 
fixed speed of 5 rpm during a 1-min observation period. 
The latency to fall from the rotating rod was automati-
cally recorded. The test was performed before surgery 
and 2, 4, 6, and 8 weeks after the injection of stem cells 
(MSCs, SPC-01, or iPSC-NPs) or saline.
Plantar Test. The plantar test was performed using an 
Ugo Basile test apparatus (Ugo Basile). A radiant ther-
mal stimulus was applied to the plantar surface of the 
paws, and the latency of the paw withdrawal response 
was measured. Each paw was stimulated five times. The 
test was performed before SCI and then weekly after SCI 
throughout the whole survival period. Hyperalgesia, as a 
response to the thermal stimulus, was defined as a signifi-
cant decrease in the withdrawal latency.
Immunohistochemical and Histological Staining
To investigate the presence of viable stem cells at the 
site of injury, MSCs were labeled with the long-term 
tracer carboxyfluorescein diacetate succinimidyl ester 
(CFDA-SE) before transplantation. Two (MSCs, n = 4; 
SPC-01, n = 3; and iPSC-NPs, n = 3) and 8 (MSCs, n = 18; 
SPC-01, n = 22; and iPSC-NPs, n = 21) weeks after trans-
plantation, the rats were transcardially perfused with 4% 
paraformaldehyde (PFA) (Penta s.r.o., Prague, Czech 
Republic) in phosphate-buffered saline (PBS), and their 
spinal cords were removed. A 2-cm-long segment of the 
spinal cord was dissected between 1 cm cranial and 1 cm 
caudal to the injury epicenter. To monitor the survival, 
migration, and differentiation of the transplanted cells, 
serial longitudinal sections of the spinal cord (14 µm) were 
cut through the areas of interest, using a Leica CM1850 
cryostat (Leica Microsystems GmbH, Vienna, Austria). 
For assessing glial scar formation, axonal sprouting, and 
the extent of spared WM/GM, tissue samples from the 
9-week survival period (e.g., 8 weeks after cell transplan-
tation) were embedded in paraffin and cut into cross sec-
tions (5-µm thickness).
To identify human cells transplanted into the rat spinal 
cord, antibodies directed against human nuclei [HuNu 
(Millipore, Billerica, MA, USA), Ku80, and human mito-
chondrial marker MTC02 (both Abcam, Cambridge, 
UK)] were used for all cells in addition to GFP label-
ing of the SPC-01 cells. To follow the fate of the trans-
planted stem cells and their interaction with the host 
tissue, antibodies directed against nestin (Millipore), glial 
fibrillary acidic protein (GFAP; Sigma-Aldrich), bIII- 
tubulin (both Sigma-Aldrich), Nkx6.1 (DSHB, Iowa 
City, IA, USA), oligodendrocyte transcription factor 2 
(Olig2), microtubule-associated protein 2 (MAP2; both 
Abcam), and doublecortin (DCX; Santa Cruz Biotech-
nology, Heidelberg, Germany) were used.
To estimate the number of implanted NPs (iPSC-
NPs and SPC-01) 2 months after implantation, every 
sixth longitudinal spinal cord section (14-µm thickness) 
was chosen. Imaging of the whole graft area per section 
was performed (Observer D1 microscope; Carl Zeiss, 
Weimar, Germany). The surviving human cells were 
recognized using HuNu staining, and the analysis was 
performed using ImageJ software [National Institutes 
of Health (NIH), Bethesda, MA, USA]. The total num-
ber of human cells that survived was estimated accord-
ing to the spinal cord volume in which the cells were 
found (number of HuNu+ sections multiplied by six). 
The percentage of surviving transplanted cells was cal-
culated by dividing the estimated total number of sur-
viving cells by the total number of transplanted cells 
(5 ´  105). Data are presented as an average per trans-
planted group.
To visualize primary antibody reactivity, appropriate 
secondary antibodies were used: goat anti-mouse immu-
noglobulin G (IgG) conjugated with Alexa Fluor 488, as 
well as goat anti-rabbit IgG conjugated with Alexa Fluor 
594 (Molecular Probes, Eugene, OR, USA). The histo-
logical and immunohistochemical evaluations were car-
ried out using a ZEISS AXIO Observer D1 microscope 
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(Carl Zeiss). Either Wizzard (Carl Zeiss), or ImageJ 
programs were used for image analysis of the histo-
logical and immunohistochemical staining. Excel 2010 
(Microsoft, Redmond, WA, USA) and CorelDRAW ´5 
(Corel Corporation, Ontario, Canada) were used to create 
the graphics.
Cresyl Violet–Luxol Staining. To distinguish the spinal 
cord WM/GM, cresyl violet (CV) and Luxol fast blue (both 
Sigma-Aldrich) staining were used on serial cross sections. 
For each sample, 15 sections were selected at 1-mm inter-
vals along the craniocaudal axis, including the lesion cen-
ter on the eighth slide. Images of the spinal cord were taken 
with an Axioskop 2 plus microscope (Zeiss, Oberkochen, 
Germany). The amounts of spared gray and white matter 
were analyzed using ImageJ software.
GAP43 Staining. For immunohistochemical analysis 
of axonal sprouting, a primary antibody against GAP43 
(Millipore) was used on serial cross sections around the 
central lesion cavity 9 weeks after SCI. For each sam-
ple, 15 sections were selected at 1-mm intervals along 
the craniocaudal axis, including the lesion center on the 
eighth slide. Images of the spinal cord were taken with 
an Axioskop 2 plus microscope. The number of GAP43+ 
fibers per slide was manually counted. The graphical pre-
sentation of these results shows the average number of 
GAP43+ fibers per slide in percentage, when compared 
with the saline group, which was set to 100%.
GFAP Staining. For immunohistochemical analysis of 
glial scaring, a CY3-conjugated primary antibody against 
GFAP was used on serial cross sections around the central 
lesion cavity 9 weeks after SCI. For each sample, 15 sec-
tions were selected at 1-mm intervals along the cranio-
caudal axis including the lesion center on the eighth slide. 
Images of the spinal cord were taken with an Axioskop 2 
plus microscope. The number of protoplasmic astrocytes 
per slice and the area of GFAP positivity surrounding the 
main lesion cavity were analyzed using ImageJ.
qPCR
The expression of rat target genes [neurotrophin-3 
(NT-3); sortilin 1 (Sort1)], FGF2, mannose receptor C type 
1 (MRC1), interferon regulatory factor 5 (IRF5), OLIG2, 
GAP43, CASP3, GFAP, vascular endothelial growth fac-
tor A (VEGFA), and ciliary neurotrophic factor (CNTF)] 
was studied using quantitative real-time polymerase chain 
reaction (qRT-PCR) at 10 and 28 days and at 2 months 
after stem cell transplantation [MSCs, n = 5 per time point; 
SPC-01, n = 5 per time point; iPSC-NPs, n = 5 per time 
point; saline (IT + IS), n = 5 + 5 per time point]. The paraffin 
sections of injured spinal cord from the region of the lesion 
epicenter (center of the lesion + 2 cranial and 2 caudal sec-
tions) were taken for the study. RNA was isolated from 
tissue cross sections using the High Pure RNA Paraffin 
Kit (Roche, Penzberg, Germany) following the manufac-
turer’s recommendations. RNA amounts were quantified 
using a spectrophotometer (NanoPhotometerTM P-Class, 
Munchen, Germany). The isolated RNA was reverse tran-
scribed into cDNA using Transcriptor Universal cDNA 
Master (Roche) and a thermal cycler (T100™ Thermal 
Cycler; Bio-Rad, Hercules, CA, USA). The qRT-PCRs 
were performed using cDNA solution, FastStart Universal 
Probe Master (Roche), and the following TagMan Gene 
Expression Assays (Life Technologies, Carlsbad, CA, 
USA): Gapdh/Rn01775763_g1, Olig2/Rn01767116_m1, 
SORT1 (NT-3)/Rn01521847_m1, Fgf2/Rn00570809_m1, 
Casp3/Rn00563902_m1, Gfap/Rn00566603_m1, Gap43/
Rn01474579_m1, Vegfa/Rn01511601_m1, Bdnf/Rn0253 
1967_s1, Cntf/Rn00755092_m1, nerve growth factor 
(Ngf)/Rn01533872_m1, Irf5/Rn01500522_m1, CD86/
Rn00571654_m1, Mrc1/Rn01487342_m1, and CD163/
Rn01492519_m1.
The qRT-PCR was carried out in a final volume of 
10 µl containing 25 ng of extracted RNA. Amplification 
was performed on a StepOnePlus™ real-time PCR cycler 
(Life Technologies). All amplifications were run under the 
same cycling conditions: 2 min at 50°C, 10 min at 95°C, 
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. 
All samples were run in duplicate, and a negative con-
trol was included in each array. Relative quantification of 
gene expression was determined using the DDCt method. 
The results were analyzed with StepOnePlus® software. 
The gene expression levels were normalized based on 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as a reference gene; control samples with vehicle (PBS) 
transplantation were used as a calibrator. The statistical 
significance of the differences between the transplanted 
and control (saline) groups was determined on DCt values 
level using a one-way analysis of variance (ANOVA) test 
with a post hoc pair-to-pair test. Differences were consid-
ered statistically significant if p < 0.05. Data are expressed 
as the mean ± the standard error of mean (SEM).
Cytokine Evaluation
The levels of cytokines were measured to analyze 
the effects of the transplantation of various stem cells 
(MSCs, SPC-01, and iPSC-NPs) on inflammation in 
the region of the lesion 10, 14, and 28 days after SCI 
(n = 5 per time point in all groups). A piece of the spi-
nal cord at the site of the lesion was dissected out and 
incubated in cell media [DMEM supplemented with 
10% fetal bovine serum (FBS); Gibco, Thermo Fisher 
Scientific, Waltham, MA, USA] and 0.2% primocin (Life 
Technologies, Thermo Fisher Scientific)47–49. To mea-
sure the levels of inflammatory cytokines, the medium 
was collected after a 24-h incubation period. Cytokine 
levels were determined using a customized Milliplex 
inflammatory cytokine kit (Millipore) and Magpix 
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instrumentation software (Thermo Fisher Scientific). Rat 
cytokine Luminex custom 8-plex kits [for IL-1b, IL-4, 
IL-2, IL-6, IL-12p70, macrophage inflammatory protein 
1a (MIP-1a), tumor necrosis factor-a (TNF-a), and reg-
ulated on activation, normal T-cell expressed and secreted 
(RANTES)] were used for customized bead assays. The 
assays were performed in 96-well filter bottom plates 
according to the manufacturer’s protocol (Thermo Fisher 
Scientific). Antibody-conjugated beads were used at a 
concentration of 5,000 beads per marker in accordance 
with the manufacturer’s protocol. Biotinylated detec-
tion antibodies were added together with streptavidin–
RPE (streptavidin–R-phycoerythrin) (both from Thermo 
Fisher Scientific), and then the levels of cytokines were 
measured on a Luminex xMAP 200 system and analyzed 
using the Magpix instrumentation software. To calculate 
the concentration of each cytokine, the raw data, con-
sisting of mean fluorescence intensity (MFI), were used. 
A four- or five-parameter logistic fit curve was gener-
ated for each cytokine from seven standards. The low-
est standard, which was at least three times above the 
background, was used to determine the lower limit of 
quantification (LLOQ).The calculation of the LLOQ was 
performed using a specific calculation by subtracting the 
MFI of the background (diluent) from the MFI of the 
lowest standard concentration, and then back calculating 
the concentration from the standard curve. The results 
are presented as the percentage change from nonlesioned 
tissue for each time point.
Statistical Analyses
All data are presented in graphs as the mean ± SEM. 
The statistical significance of differences between the 
MSC- , SPC-01-, iPSC-NP-, and saline-injected groups 
was determined using either one-way ANOVA or two-
way ANOVA in the case of a second factor (time). In the 
case of repeated measurements (behavioral tests) or the 
spatial distribution of the treatment effect (gray/white 
matter sparing, glial scar distribution), two-way repeat-
ed-measures (RM) ANOVA was used. The Student–
Newman–Keuls (SNK) post hoc pair-to-pair test was 
used to specify for which groups and at which time points 
were the changes significant (all in Sigmastat 3.1; Systat 
Software Inc., San Jose, CA, USA). Differences were 
considered statistically significant if p < 0.05.
RESULTS
Cell Fate and the Pattern of Discrete 
Differentiation Following Stem Cell Implantation
The survival of IT (MSCs) and IS (SPC-01 and iPSC-
NPs) grafted cells was evaluated 2 weeks and 2 months 
postimplantation, respectively. Only a few MSCs were 
observed partially attached to the dorsal spinal cord 
surface (Fig. 1A) 2 weeks after application, and none 
were detected 2 months postgrafting. In contrast, notice-
ably high numbers of neural precursors derived from 
either SPC-01 cells (16 ± 3%) or iPSC-NPs (11 ± 3%) 
were detected around the injection site at 2 months after 
implantation (Fig. 1B and C). Both types of human NPs 
2 months after implantation remained rather immature. 
SPC-01 cells were predominantly positive for GFAP 
(Fig. 1D) or for early neural markers such as  nestin 
(Fig. 1E), olig2 (Fig. 1F), and Nkx6-1. Most of the 
iPSC-NPs were positive for bIII-tubulin (Fig. 1G), Map2 
(Fig. 1H), and DCX (Fig. 1I), with only some of the 
grafted cells being GFAP+ (Fig. 1J) (for more details, see 
http://www.iem.cas.cz/en/research/departments/tissue_
culture/supplementary_documents.html).
Functional Recovery From SCI Following  
Stem Cell Implantation
The BBB test was performed once a week after lesion 
induction to evaluate hindlimb locomotor recovery. All 
stem cell-treated rats performed significantly better when 
compared with saline-treated animals. Additionally, 
iPSC-NP- and MSC-injected rats were superior to the 
SPC-01-treated group (two-way RM ANOVA, treatment; 
p < 0.001; for p values of post hoc pair-to-pair test, see 
http://www.iem.cas.cz/en/research/departments/tissue_
culture/supplementary_documents.html) (Fig. 2A).
The recovery of advanced locomotor function was 
evaluated using the flat beam test. In this test, rats grafted 
with iPSC-NPs showed the greatest degree of improve-
ment when compared to the saline-treated animals as well 
as other stem cell groups. However, probably because of 
the severe injury and higher level of coordination and 
muscle strength that is needed for the flat beam test, not 
all cell-treated groups showed significant improvement 
when compared to saline-injected rats (two-way RM 
ANOVA, treatment; p < 0.001; for p values of post hoc 
pair-to-pair test, see http://www.iem.cas.cz/en/research/
departments/tissue_culture/supplementary_documents.
html) (Fig. 2B).
The time score in the flat beam test reflected the time 
it took to cross the beam within a 60-s test period; the test 
was performed starting from the third week onward after 
treatment. The iPSC-NP-treated rats showed a marked 
ability to cross the beam in a shorter time interval than 
any other group and displayed progressive improvement 
over the experimental period; no other group showed a 
significant improvement during the measurement period 
(two-way RM ANOVA, treatment; p < 0.001; for post hoc 
pair-to-pair test p values, see http://www.iem.cas.cz/en/
research/departments/tissue_culture/supplementary_
documents.html) (Fig. 2C).
To determine long-term weight support and endur-
ance and footstep coordination, the rotarod test was 
used. As expected, because of the difficulty of the test, 
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Figure 1. Survival of implanted stem cells and differentiation pattern of SPC-01 and iPSC-NP cells following their implantation 
after SCI. Only a few MSCs were detected on the spinal cord surface 2 weeks after application (A), while SPC-01 cells (B) and 
iPSC-NPs (C) survived robustly for at least 2 months after implantation. Arrows mark the attached MSCs. Insets (A1–A3) show 
the MSC morphology. Staining for MTCO2 (B, C) or CFDA-SE (A) was used to detect the implanted cells in the injured spinal 
cord. The differentiation patterns of SPCs (D–F) and iPSC-NPs (G–J) demonstrated that the majority of SPCs differentiated into 
astrocytes (D) or remained immature (E, F), while on the other hand transplanted iPSC-NPs expressed mainly neuronal markers 
(G–I) and less astrocytic markers (J). (D), (F)–(H), and (J) were taken from the edge of the graft, (E) is from the graft center, and 
(I) shows cell migration into the host tissue (Orto images are online in additional files http://www.iem.cas.cz/en/research/depart 
ments/tissue_culture/ supplementary_documents.html). Scale bars: 300 µm (A), 500 µm (B, C), 20 µm (A1, A2, A3, D–J). CFDA-SE, 
carboxyfluorescein diacetate succinimidyl ester; MTC02, anti-mitochondria antibody; HuNu, human nuclei (all green); DAPI, 4¢,6-
diamidin-2-fenylindol (blue); MSC, mesenchymal stem cell; iPSC-NPs, human induced pluripotent stem cell-derived neural precur-
sors; OLIG2, oligodendrocyte transcription factor 2; DCX, doublecortin; SPC, spinal fetal cell; SCI, spinal cord injury.
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no significant differences in stem cell-treated rats were 
observed when compared with saline-treated animals 
(two-way RM ANOVA, treatment; p > 0.05; for p values 
of post hoc pair-to-pair test, see http://www.iem.cas.cz/
en/research/departments/tissue_culture/supplementary_
documents.html) (Fig. 2D).
Changes in the sensory function of the hindlimb after 
SCI (increased sensitivity to a thermal stimulus) were 
determined using the plantar test apparatus (Ugo Basile). 
Hyperalgesia is generally correlated to the pathological 
state induced by SCI as well as to sensory function adapta-
tion over time. All stem cell-treated animals were similar 
Figure 2. Locomotor and sensory recovery following stem cell transplantation after SCI. Recovery from SCI after the administra-
tion of MSCs, SPC-01 cells, or iPSC-NPs. The locomotor ability of saline- or stem cell-treated rats was assessed using the BBB 
(A), flat beam (B), time score (C), and rotarod tests (D). All treated animals showed significantly higher performances in the open-
field BBB test in comparison with saline controls (A). Additionally, the iPSC-NP and MSC groups demonstrated significantly higher 
performances compared to the other treatment group. In tests requiring more advanced locomotor skills, such as the flat beam test 
(B), all treated groups showed a significant difference when compared with the saline group, but with a dominance of iPSC-NP. For 
the rotarod test (D), for which body weight-supported stepping is essential, a stable but insignificant trend of iPSC-NPs in higher 
performance was observed. Thermal nociception was assessed using the plantar test (E) after stem cell or saline transplantation, and 
no additional hyperalgesia after grafting of stem cells was observed. *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus 
SPC-01; ¤p < 0.05 versus iPSC-NPs. For p values, see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_
documents.html. BBB, Basso, Beattie, and Bresnahan test; BI, before injury; MSC, mesenchymal stem cell; iPSC-NPs, human induced 
pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord injury; TX, stem cell transplantation.
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to the saline-treated group, which implies that no addi-
tional hyperalgesia appeared following stem cell trans-
plantation (two-way RM ANOVA, treatment; p > 0.1; for 
p values of post hoc pair-to-pair test, see http://www.iem.
cas.cz/en/research/departments/tissue_culture/supple 
mentary_documents.html) (Fig. 2E).
Estimation of White and Gray Matter Sparing 
Following Stem Cell Treatment After SCI
The area of spared WM/GM in the spinal cord (µm2 
per cross section) was measured on 15 CV–Luxol-stained 
spinal cross sections 2 months after injury. The values 
presented in Figure 3A are given in relation to the areas 
measured in saline-treated control animals, which were 
set as 100%. Despite the observed impact of all stem 
cell types on WM/GM sparing, only the implantation of 
iPSC-NPs showed a statistically significant preservation 
of WM/GM, in comparison with saline-treated as well as 
other stem cell-treated animals (two-way RM ANOVA, 
treatment; p < 0.001; for p values of post hoc pair-to-pair 
test, see http://www.iem.cas.cz/en/research/departments/
tissue_culture/supplementary_documents.html) (the sta-
tistical significance within the link) (Fig. 3A, a1–a3).
Astrogliosis and Morphological Changes in GFAP+ 
Cells Following Stem Cell Transplantation
The area of the glial scar surrounding the central lesion 
was measured on 15 GFAP–cyanine 3 (CY3)-stained spi-
nal cord cross section slices 2 months after injury. The 
values shown in Figure 3B are presented as the percentage 
of the GFAP+ area compared to the total tissue area. All 
stem cell-treated groups had significantly smaller GFAP+ 
volume compared to saline-treated animals, when calcu-
lated as a sum of area of single slices. Additionally, rats 
grafted with SPC-01 cells or iPSC-NPs had significantly 
smaller GFAP+ volume in comparison with rats receiving 
MSCs (two-way RM ANOVA, treatment; p < 0.001; for 
p values of post hoc pair-to-pair test, see http://www.iem.
cas.cz/en/research/departments/tissue_culture/supple 
mentary_documents.html) (Fig. 3B, b1, b2). Moreover, 
the effect of stem cells on GFAP phenotype after SCI was 
shown. Rats injected with saline, MSCs, or SPC-01 cells 
had a significantly higher number of protoplasmic astro-
cytes per slice in comparison with the iPSC-NP group 
(two-way RM ANOVA, treatment; p < 0.05; for p values 
of post hoc pair-to-pair test, see http://www.iem.cas.cz/
en/research/departments/tissue_culture/supplementary_
documents.html) (Fig. 3B, b3, b4).
Determination of Axonal Sprouting Following 
Stem Cell Implantation After SCI
The number of GAP43+ fibers was calculated in cross 
sections of injured spinal cords 2 months after injury. The 
values presented in Figure 3C are given in relation to 
the value found in saline-treated animals, which was set 
as 100%. A higher number of GAP43+ fibers in the spi-
nal cord cross sections of both types of NP-transplanted 
rats were observed, when compared to both saline- 
and MSC-treated animals (two-way RM ANOVA, treat-
ment; p < 0.05; for p values of post hoc pair-to-pair 
test, see http://www.iem.cas.cz/en/research/departments/
tissue_culture/supplementary_documents.html) (Fig. 3C, 
c1–c3).
M1 and M2 Macrophage-Related Gene Expression 
in Response to Stem Cell Transplantation After SCI
The expression of genes related to the macrophage 
phenotypes M1 (IRF5 and CD86) and M2 (MRC1 and 
CD163) was determined by qRT-PCR from spinal cord 
samples taken from the lesion site 10 and 28 days after 
cell transplantation. Ten days after SCI, spinal cord tis-
sue treated with MSCs revealed the upregulation of IRF5 
( p < 0.05) and MRC1 when compared to the control tis-
sue. Gene expression remained unaltered in samples 
taken from the SPC-01-treated spinal cords. On the other 
hand, iPSC-NP-treated rats showed a downregulation of 
CD86 and CD163, markers of M1 and M2 macrophages, 
respectively (Fig. 4A, a1). Twenty-eight days after graft-
ing, all of the studied genes related to M1 and M2 mac-
rophages were upregulated; however, this upregulation 
remained statistically insignificant (post hoc pair-to-pair 
test; for p values, see http://www.iem.cas.cz/en/research/
departments/tissue_culture/supplementary_documents.
html) (Fig. 4A, a2).
Expression of Intrinsic Genes After  
Stem Cell Treatment of SCI
The relative expression of rat genes related to growth 
factors [SORT1 (NT-3), FGF2, CNTF, and BDNF], apo-
ptosis (Casp3), vascularization (VEGFA), axonal sprout-
ing (GAP43), astrogliosis (GFAP), and oligodendrocytes 
(OLIG2) following stem cell transplantation was deter-
mined 10 (Fig. 4B, b1) and 28 (Fig. 4B, b2) days and 
2 months (Fig. 4B, b3) after SCI. Ten days after SCI 
(3 days after grafting), animals with implanted MSCs 
displayed an elevated expression of all genes of inter-
est as a strong but insignificant trend. Similar levels of 
gene expression in the MSC-treated group continued 
after 28 days, apart from the downregulated expres-
sion of Casp3. Two months after SCI, the MSC group 
showed a significant downregulation of BDNF, VEGF, 
and NGF in comparison with the saline- and both 
NP-treated groups. The transplantation of SPC-01 cells 
and iPSC-NPs did not cause any notable changes in gene 
expression at any of the time points; however, a gradual 
alteration in gene expression, mostly pertaining to genes 
related to recovery processes, was observed at 28 days as 
well as 2 months after SCI (Fig. 4B, b2, b3). The greatest 
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upregulation of gene expression was found for FGF2; how-
ever, this change was not significant (post hoc pair-to-pair 
test; for p  values, see http://www.iem.cas.cz/en/research/ 
departments/tissue_culture/supplementary_documents.
html) (Fig. 4B, b1 and b2).
Changes in Cytokine Profiles After  
Stem Cell Treatment Following SCI
To determine the inflammatory response following 
treatment with MSCs, SPC-01 cells, or iPSC-NPs, the 
levels of cytokines (MIP-1a, IL-4, IL-1b, IL-2, IL-6, 
IL-12p70, TNF-a, and RANTES) were assayed at 10, 14, 
and 28 days after SCI. The levels of MIP-1a, IL-2, and 
TNF-a were decreased relatively to those of the saline-
treated controls at 10 days post-SCI in all three stem cell 
groups and persisted through day 14. At day 28 in the MSC 
group, the MIP-1a, IL-2, and TNF-a levels increased 
in comparison with those of other groups. The levels of 
RANTES remained significantly depressed below saline 
control levels in the SPC-01 and iPSC-NP groups, while 
its concentration was above control levels in the MSC 
group. IL-4 levels were reduced in MSC-treated animals 
at day 10 and increased insignificantly at day 28. In con-
trast, levels of IL-4 in both NP groups gradually increased 
when compared to that of the saline group. The levels 
of IL-1b were insignificantly lowered compared to that 
of the controls at day 10 in MSC and SPC-01 groups, 
and significantly in the case of the iPSC-NP group. 
At 14 and 28 days after SCI, levels of IL-1b remained 
similar to those of the saline-treated group, apart from 
an increase in the SPC-01 group on day 14 after SCI. 
IL-6 and IL-12p70 levels were noticeably higher in both 
NP groups compared to the control and MSC groups. 
This pattern continued throughout the whole experi-
mental period (post hoc pair-to-pair test; for p values, see 
http://www.iem.cas.cz/en/research/departments/tissue_ 
culture/supplementary_documents.html) (Fig. 4C, c1–c3).
DISCUSSION
This investigation demonstrates the effectiveness of 
MSCs and two NPs derived from either human fetal spi-
nal cord precursors (in our study SPC-01) or from iPSCs 
(iPSC-NPs) in the cell therapy of SCI. In detail, it pro-
vides a description of the different mechanisms under-
lying their support of SCI recovery, in particular the 
survival and differentiation patterns, as well as the anti-
inflammatory action of these cells, which together govern 
the repair and recovery process.
The intrathecal application of MSCs and the intraspi-
nal application of SPC-01s and iPSC-NPs were chosen 
as the routes of delivery. Stem cell properties in vivo 
and their impact on behavior recovery and the physi-
ological changes related to SCI are closely associated 
with the mode of their administration, that is, local or 
systemic18,50,51. Nevertheless, meta-analyses of behav-
ioral recovery after MSC application in experimental 
rat models of SCI failed to detect any statistically sig-
nificant differences in locomotor recovery between intra-
parenchymal, intrathecal, or intravenous administration14. 
Intrathecal administration of MSCs has been proposed 
to be a less invasive method52, and this route is not only 
well suited to multiple injections over an extended time 
period, but also by using an intrathecal catheter, the treat-
ment can be administered closer to the injury site, thereby 
increasing the local concentration of MSCs. In our study, 
we applied MSCs IT since our previous study using intra-
parenchymal injections of rat MSCs into a balloon com-
pression model of SCI resulted in a similar recovery as 
that seen in animals following intrathecal application5,7. 
It is also widely accepted that the effect of MSCs is 
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Figure 3. Histological and immunohistochemical analysis 2 months after SCI. (A) The extent of spared white (a1) and gray (a2) matter 
was determined 2 months after SCI in rats treated with saline or stem cells (MSC, SPC-01, and iPSC-NP). CV (a3 and GM) was used 
for gray matter staining, while Luxol blue was used to stain the white matter (a3 and WM). Both the WM/GM surface areas were calcu-
lated according to the example on an illustrative image (a3). All implanted cells had a positive impact on tissue sparing in the WM/GM 
of the injured spinal cord. However, only the iPSC-NP group showed a statistically significant preservation of spinal tissue. (B) The 
effect of implanted MSCs, SPC-01, and iPSC-NP cells on glial scar formation, showing the area of astrogliosis surrounding the main 
cavity as a percentage of the total tissue area (b1, b2) and the average number of protoplasmic astrocytes per section (b3, b4) around the 
central lesion cavity 9 weeks after SCI. Illustrative images show GFAP-CY3 staining of the glial scar (b2) and protoplasmic astrocytes 
(b4). Scale bars: 500 µm (b2, b4). Both neural precursors reduced glial scaring and the number of protoplasmic astrocytes, whereas 
MSCs modulated the distribution of glial scarring and only mildly reduced it. (C) The effect of implanted MSC, SPC-01, and iPSC-NP 
cells on axonal sprouting (c1). The numbers of GAP43+ fibers (15 sections per rat) are presented as percentages relative to the number 
of positive fibers following saline treatment (set to 100%). Illustrative image of a GAP43+-labeled section (c2) with grafted cells. 
Illustrative image of positive nuclear staining for Ku80, indicating cells of human origin (c3); arrows show GAP43+ fibers. Scale bars: 
500 µm (c2), 20 µm (c3). *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus SPC-01; ¤p < 0.05 versus iPSC-NPs. For 
p values of (A)–(C), see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_documents.html. MSC, mes-
enchymal stem cell; iPSC-NPs, human induced pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord 
injury; GM, gray matter; WM, white matter; GFAP-CY3, glial fibrillary acidic protein cyanine 3; GAP43, growth-associated protein 
43; HuNu, human nuclei.
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mainly paracrine, and the cells do not differentiate into 
neural cells9, so there is no necessity to have them grafted 
into the parenchyma from the point of functional inte-
gration. In addition, the intrathecal application of MSCs 
has often been used in recent clinical trials53–55 and is less 
invasive for patients. Moreover, the intrathecal applica-
tion of MSCs in an animal model of amyotrophic lateral 
sclerosis (ALS) prolonged life span, reduced apopto-
sis, and preserved the number of motoneurons and their 
perineural nets56. On the other hand, the administration of 
iPSC-NPs into the intrathecal space of lesioned rats had 
much less effect when compared with intraspinal injec-
tion57. Moreover, NPs can differentiate into neural cells, 
which can contribute to spinal cord repair. Therefore, 
an injection into the spinal parenchyma was chosen for 
both NPs.
In correspondence with our results, several studies 
have shown that the subacute grafting of MSCs5,7,58,59, 
iPSC-NPs23,28, or NPs derived from either fetal tissue or 
ESCs17,18,26,60,61 leads to the improvement of locomotor 
recovery. However, the mechanisms underlying the cells’ 
effects on locomotor recovery may vary depending on 
the methods and approaches utilized25. In our study, the 
highest behavioral scores were observed in the iPSC-NP-
treated animals when compared not only to saline-treated 
animals but also to other cell-treated groups. This out-
come was observable in the basic and advanced locomo-
tor settings. In contrast to the other treatment groups, the 
iPSC-NP-treated rats extended occasional weight sup-
port at 9 weeks after SCI. Surprisingly, the high effect on 
locomotor recovery was also observed in the MSC group. 
Since the rapid recovery in all stem cell-treated animals 
was observed within weeks after grafting, the impact of 
stem cell treatment was caused by a paracrine effect in all 
three types of cells (Fig. 2A–C).
The significant paracrine effect following the intraspi-
nal grafting of both types of NP cells was most likely 
due to their ability to robustly survive for the entire 
experimental period in conjunction with the matura-
tion and differentiation of these cells, which provided a 
continuous supply of new cells to the injured host tis-
sue. These findings are in agreement with those of other 
authors19,23,24,26,28,36. Furthermore, the ability of iPSC-NPs 
to differentiate into a neuronal phenotype was clearly 
evidenced (Fig. 1); yet on the other hand, clusters of 
grafted SPC-01 cells formed structures resembling dense 
clouds, with only a few host neurofilaments penetrating 
the graft. These cells differentiated mainly into astrocytes 
and displayed less communication with the tissue, as 
observed previously19,26. It is important to note that at the 
end of this study, the implanted NPs were only partially 
matured, since the full maturation of human cells requires 
a longer period.
In our study, in a time period matching the MSC sur-
vival period after implantation, elevated levels of endog-
enous VEGF, CNTF, and FGF2 were found. Increased 
levels of VEGF are tightly connected with angiogenesis, 
which is highly desirable for vitalizing lesioned tissue62,63, 
and CNTF is a promising factor in the treatment of SCI, 
with a strong neuroprotective effect in both the CNS and 
also the peripheral nervous system (PNS)64. The presence 
of CNTF promotes the differentiation and maturation of 
oligodendrocyte precursor cells into oligodendrocytes. 
Additionally, CNTF promotes mature  oligondendrocyte 
survival. Increased CNTF levels may thus serve to 
improve remyelination after SCI65,66. In our study, the 
intrinsic CNTF expression was significantly lower in 
the iPSC-NP-implanted group when compared to MSC-
treated animals. Together with other elevated growth fac-
tor levels found in the rats treated with MSCs, this could 
be one of the reasons why, despite worse results in other 
analyses, MSC-treated animals exhibited some of the 
improvement in locomotor function seen in the iPSC-NP-
treated group.
Recently, the strategies using MSCs in experimen-
tal treatment of CNS injuries and degenerative diseases 
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Figure 4. Effect of stem cell implantation on the inflammatory response and the gene expression of factors related to recovery after 
SCI. (A) Relative expression of macrophage-related genes (M1-CD86, IRF5; M2-CD163, MRC1) in response to grafted MSCs, 
SPC-01, and iPSC-NP cells 10 and 28 days after SCI, demonstrating that the most significant changes were evident following MSC 
treatment, when IRF5 upregulation was observed 10 days after SCI. The expression levels measured in saline-treated rats were set to 0. 
(B) Relative gene expression of factors related to the recovery process in response to grafted MSCs, SPC-01, or iPSC-NP cells 10 days 
(b1), 28 days (b2), and 2 months (b3) after SCI. The expression levels in saline-treated rats were set to 0. (C) The levels of cytokines 
and chemokines related to inflammation are presented following stem cell treatment 10 (c1), 14 (c2), and 28 (c3) days after SCI, which 
correspond to 3, 7, and 21 days after implantation. The levels measured in animals with no lesion were set to 100% as indicated by a 
horizontal line in the graphs. *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus SPC-01; ¤p < 0.05 versus iPSC-NPs. For 
p values of (A)–(C), see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_documents.html. MSC, mes-
enchymal stem cell; iPSC-NP, human induced pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord 
injury; IRF5, interferon regulatory factor 5; MRC1, mannose receptor C type 1; SORT1, sortilin 1; FGF, fibroblast growth factor; 
OLIG2, oligodendrocyte transcription factor 2; GAP43, growth-associated protein 43; GFAP, glial fibrillary acidic protein; VEGF, 
vascular endothelial growth factor; CNTF, ciliary neurotrophic factor; BDNF, brain-derived neurotrophic factor; NGF, nerve growth 
factor; NT-3, neurotrophin-3; MIP, macrophage inflammatory protein; TNF-a, tumor necrosis factor a; RANTES, regulated on activa-
tion, normal T-cell expressed and secreted.
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have focused on MSC-produced secretomes, instead of 
cell therapy itself 67. These secretomes are defined by 
specific conditions of cultivation, and the effect of their 
application could be different than the use of MSCs68–70. 
This opens up new possibilities for combinatory thera-
pies based on MSC secretomes as a conditional pretreat-
ment for NP implantation71. Despite these tendencies, the 
majority of preclinical investigations and clinical trials 
are still using a cellular approach.
In most cases, the improvements in locomotor or sen-
sory deficits can be correlated with the preservation of 
WM/GM after SCI72–74. MSCs have been described as 
immunomodulatory and proregenerative. Their para-
crine effect (secretome) has proven to be beneficial in 
CNS regeneration67,75. In our study, the weaker effect 
on tissue sparing observed in MSC-treated animals was 
perhaps due to the absence of MSCs in the tissue paren-
chyma, thus reflecting a purely paracrine effect as the 
MSCs never made direct contact with the host tissue. On 
the other hand, both types of NPs, which were directly 
injected into the lesion, displayed robust survival in con-
junction with the maturation and differentiation of these 
cells, suggesting their involvement in the partial recon-
struction of damaged tissue, which was also reflected by 
the extent of spared WM/GM, more effective glial scar 
modulation, and robust axonal sprouting, when compared 
to saline- or MSC-treated animals (Fig. 3). These findings 
are in agreement with those of other authors19,23,24,26,28,36.
The tissue response to the implantation of both NPs 
and MSCs in terms of up- or downregulated expression 
levels of genes of interest correlates with the observed 
differences in glial scar remodulation (GFAP expression 
vs. GFAP-CY3 staining) and tissue sparing (Casp3) after 
SCI, where the most contradictory effects were observed 
between the iPSC-NP and MSC groups. The intrinsic 
growth factor production in the NP-treated rats 2 months 
after SCI (BDNF, VEGF, and NGF), even though not 
significantly higher than saline-treated animals, showed 
a long-term stable trend toward upregulation, which 
might explain the superior impact of both types of NPs 
on tissue modulation.
The macrophage response reflects the type of immune 
response after SCI. The ratio of M1/M2 macrophages 
after injury is thought to reflect the balance of the pro-/
anti-inflammatory response. This balance may result in 
the increased integration of implanted cells, influence 
their migratory abilities, and lead to enhanced recovery 
after SCI76. The attenuation of this balance by the applica-
tion of stem cells77,78 or immunomodulatory molecules79,80 
is currently of great interest. In our study, the M1/M2 
macrophage gene expression profile after SCI in the cell-
treated animals was slightly shifted toward M2 specific, 
which might be associated with the observed differences 
in tissue sparing as well as glial scar formation.
In this study we also evaluated the levels of cytokines 
in response to stem cell grafting. The immune response 
of the spinal tissue can differ from the systemic response 
and can provide relevant answers to questions regarding 
cell survival and the route of application. The most pro-
found changes in the immunologic response to implanted 
stem cells were seen in the levels of MIP-1a, TNF-a, 
RANTES, IL-1 b, IL-4, IL6, and IL12.
The reduction of MIP-1a and RANTES was most pro-
nounced in the SPC-01 and iPSC-NP groups when com-
pared to both control and MSC-treated rats. The MIP-1a 
has been implicated in the phagocytosis of myelin after 
SCI and is a reliable marker of inflammation81, and the 
reduction of RANTES using the anti-inflammatory com-
pound curcumin has been demonstrated to decrease the 
size of the lesion cavity82, increase neuronal viability, and 
decrease cell death83. The response of both NPs nicely 
reflects their impact on tissue preservation and axonal 
sprouting. TNF-a has long been used as a target for anti-
inflammatory therapy. In SCI, TNF-a induces apoptosis 
via an NF-kB-dependent mechanism as well as a mito-
chondrial pathway regulated by the B-cell lymphoma 2 
(BCL-2) family protein, Bax84. Inhibitors of TNF-a in 
the rat model of SCI have been proven to be an impor-
tant cofactor for successful therapy85. In our study, the 
strongest effect on TNF-a was observed in the iPSC-NP 
group. Therefore, our results show that iPSC-NPs may be 
the most potent stem cell population, given that they most 
strongly suppressed TNF-a. MSCs have been described 
to suppress TNF-a levels after neuronal damage78. In 
our study, this effect was also transiently achieved in the 
MSC-treated animals.
The levels of IL-1b distinguish the two neural precur-
sor populations from each other, since the levels in the 
SPC-01-treated group were significantly higher at day 14 
when compared to the control groups, while these levels 
remained unchanged and below control values in the 
iPSC-NP group. The IL-1b levels in the MSC group were 
unchanged throughout the study. IL-1b has been impli-
cated as a proinflammatory cytokine, whose inhibition 
may prove to be beneficial in SCI86. The levels of IL-1b 
in the MSC- and saline-treated animals remained undis-
tinguished throughout the study. On the other hand, the 
increased IL-1b level in the SPC-01-treated group (day 14), 
and the initial decreased levels in iPSC-NP group when 
compared to the saline-treated animals, may partially 
reflect the impact of their origin and correlate to recovery 
after SCI.
IL-4 has been proposed to play an anti-inflammatory 
role. Therefore, the increase in IL-4 levels at day 14 in 
both the SPC-01 and iPSC-NP groups may be beneficial 
and promote recovery. Specifically, IL-4-mediated argi-
nase may promote recovery and reduce inflammation87. 
When IL-4 was neutralized in a rat model of SCI, more 
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extensive cavitation was noted 4 weeks after injury88. 
Therefore, increased levels of IL-4 in the SPC-01 and 
iPSC-NP groups, as observed at days 14 and 28 in our 
study, may contribute to neuroprotection, leading to the 
reduction of secondary injury or gliosis. In MSC-treated 
animals, 10 and 14 days after SCI, a decrease in IL-4 was 
observed when compared with both saline- and NP-treated 
rats. This is in agreement with elevated IRF5 and MRC1 
RNA levels following macrophage stimulation.
IL-6 remains a cytokine with dual functions. On the 
one hand, it has been demonstrated to modulate the 
immune response by increasing inflammation after SCI. 
High levels of IL-6 can shift NSC differentiation toward 
astrocytes rather than neurons, thus promoting glial scar 
formation89. Additionally, suppression of IL-6 levels 
reduces secondary injury by reducing inflammatory cell 
infiltration90 and may result in improved recovery after 
SCI91. On the other hand, a mild level of IL-6 is important 
for preserving neurogenesis and neuroprotection follow-
ing CNS injuries92,93. Moreover, IL-6 has been shown to 
inhibit voltage-gated sodium channel currents, indicating 
a potentially neuroprotective role against excitotoxic-
ity94. In our study, MSCs partially decreased IL-6 levels, 
while high levels of IL-6 were observed in the SPC-01 
and iPSC-NP groups. Nevertheless, based on our obser-
vations, we believe that IL-6 remains a cytokine with 
dual functions. IL-12p70 may play an anti-inflammatory 
role, as its levels have been shown to decrease after SCI95 
(Fig. 4). Targeted administration of IL-12 has been shown 
to induce remyelination and de novo neurogenesis96 
and partially prevents T-mediated demyelination97 after 
 neuronal damage and neurodegeneration. This evidence 
suggests that increased IL-12p70 levels may play an anti-
inflammatory role and could be desirable after SCI, as 
seen in the SPC-01 and iPSC-NP groups.
CONCLUSION
In our experimental setting, and taking into consid-
eration two different routes of application, the use of 
iPSC-NPs to treat a balloon compression SCI positively 
affected the majority of studied factors involved in spinal 
cord regeneration, such as glial scar formation, axonal 
sprouting, tissue sparing, and cytokine levels. The cumu-
lative effect resulted in better performance in advanced 
locomotor tests (flat beam test and rotarod) requiring bet-
ter movement coordination. The application of SPC-01 
cells, despite their long-term survival and effect on axonal 
sprouting, has not shown the potential of iPSC-NPs on 
behavioral recovery. On the other hand, the implantation 
of MSCs, despite their limited survival period, led to a 
significant improvement in locomotor abilities, which 
might be connected with their initial effect on intrinsic 
growth factor production and suppression of the immune 
response. Strategies to prolong MSC survival and to 
extend their effect on injured tissues by repeated appli-
cation should be taken into account in future studies. To 
fully support the potential of iPSC-NPs for SCI treat-
ment, the cells should be prepared by techniques that do 
not require viral integration.
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